Prospective, Multicentre, Open Label, Non-Controlled, 24-Week Observation in Type 2 Diabetics Using Once Daily Levemir (Insulin Detemir) as Part of Their ITT Regimen.

Trial Profile

Prospective, Multicentre, Open Label, Non-Controlled, 24-Week Observation in Type 2 Diabetics Using Once Daily Levemir (Insulin Detemir) as Part of Their ITT Regimen.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Insulin detemir (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LITHULEV1
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Nov 2010 Actual end date changed from Jan 2010 to Dec 2009 as reported by ClinicalTrials.gov.
    • 25 Mar 2010 Actual end date changed from Dec 2009 to Jan 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top